

University of Groningen

Microenvironment, cross-talk, and immune escape mechanisms

Visser, Lydia; Veldman, Johanna; Poppema, Sibbrand; van den Berg, Anke; Diepstra, Arjan

Published in:
 Hematologic Malignancies

DOI:
[10.1007/978-3-030-32482-7_4](https://doi.org/10.1007/978-3-030-32482-7_4)

IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from it. Please check the document version below.

Document Version
 Publisher's PDF, also known as Version of record

Publication date:
 2020

[Link to publication in University of Groningen/UMCG research database](#)

Citation for published version (APA):

Visser, L., Veldman, J., Poppema, S., van den Berg, A., & Diepstra, A. (2020). Microenvironment, cross-talk, and immune escape mechanisms. In *Hematologic Malignancies* (pp. 69-86). (Hematologic Malignancies). Springer. https://doi.org/10.1007/978-3-030-32482-7_4

Copyright

Other than for strictly personal use, it is not permitted to download or to forward/distribute the text or part of it without the consent of the author(s) and/or copyright holder(s), unless the work is under an open content license (like Creative Commons).

The publication may also be distributed here under the terms of Article 25fa of the Dutch Copyright Act, indicated by the "Taverne" license. More information can be found on the University of Groningen website: <https://www.rug.nl/library/open-access/self-archiving-pure/taverne-amendment>.

Take-down policy

If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.

Downloaded from the University of Groningen/UMCG research database (Pure): <http://www.rug.nl/research/portal>. For technical reasons the number of authors shown on this cover page is limited to 10 maximum.



Microenvironment, Cross-Talk, and Immune Escape Mechanisms

4

Lydia Visser, Johanna Veldman, Sibrand Poppema,
Anke van den Berg, and Arjan Diepstra

Contents

4.1	Microenvironment	70
4.1.1	Hodgkin Lymphoma Subtypes	70
4.1.2	Epstein-Barr Virus	70
4.1.3	Human Immunodeficiency Virus	71
4.1.4	T Cell Subsets in cHL	71
4.1.5	T Cell Subsets in NLPHL	73
4.1.6	Fibrosis and Sclerosis	74
4.1.7	Eosinophils, Plasma Cells, Mast Cells, and B Cells	74
4.2	Cross-Talk between HRS Cells and Microenvironment	74
4.2.1	Factors Supporting Tumor Growth	74
4.2.2	Shaping the Environment	76
4.3	Immune Escape Mechanisms	77
4.3.1	Antigen Presentation	77
4.3.2	HLA Class I Expression	78
4.3.3	HLA Class II Expression	78
4.3.4	Immune Checkpoints	79
4.3.5	Immunosuppression	80
4.4	Prognostic Impact of the Microenvironment	81
4.5	Conclusion	81
	References	81

L. Visser · J. Veldman · S. Poppema
A. van den Berg · A. Diepstra (✉)
Department of Pathology and Medical Biology,
University Medical Center Groningen, University
of Groningen, Groningen, The Netherlands
e-mail: l.visser@umcg.nl; j.veldman@umcg.nl;
s.poppema@rug.nl; a.van.den.berg01@umcg.nl;
a.diepstra@umcg.nl

4.1 Microenvironment

4.1.1 Hodgkin Lymphoma Subtypes

When discussing the microenvironment in Hodgkin lymphoma (HL), it is important to recognize the different HL subtypes described by the WHO classification [1, 2]. The classical HL (cHL) subtypes are defined in large part by the composition of the reactive infiltrate (Table 4.1). The most prevalent subtype is the nodular sclerosis type that consists of a nodular background with thick fibrotic bands, usually with a thickened lymph node capsule. In addition to the lacunar type of Hodgkin/Reed-Sternberg (HRS) cells, there is a microenvironment consisting of T cells, eosinophils, and histiocytes, with a variable admixture of neutrophils, plasma cells, fibroblasts, and mast cells. The second most common subtype is mixed cellularity, which is defined by the presence of typical HRS cells and a diffuse infiltrate of T cells, eosinophils, histiocytes, and plasma cells, sometimes with the formation of granuloma-like clusters or granulomas (Fig. 4.1). Lymphocyte-rich cHL also comprises typical HRS cells in a nodular or diffuse microenvironment and small B and/or T lymphocytes dominating the background, sometimes with admixture of histiocytes. Granulocytes are not present in this subtype. The rare lymphocyte-depleted subtype harbors a high percentage of HRS cells in a background consisting of fibroblasts and a low number of T cells. Nodular lymphocyte predominance (NLP) HL is an entity that is fundamentally different from cHL. The morphology may closely resemble that of the nodular variant of the classical lymphocyte-rich subtype, both involving follicular areas with

many small B cells, but NLPHL can also show other growth patterns [3]. The characteristics of the tumor cells and the T cells in NLPHL are different from cHL. HRS cells show a loss of B cell phenotype, while in NLPHL the lymphocyte-predominant (LP) tumor cells share many markers with germinal center B cells. The T cells in cHL have features of paracortical T cells, while those in NLPHL are similar to germinal center T cells (T follicular helper cells) [4–6].

4.1.2 Epstein-Barr Virus

The presence of latent Epstein-Barr virus (EBV) genomes in HRS cells appears to influence the composition of the microenvironment. Positive EBV status is strongly associated with the mixed




Fig. 4.1 The microenvironment in mixed cellularity classical Hodgkin lymphoma. *RS* classical Reed-Sternberg cell, *H* mononuclear Hodgkin tumor cell, *T* T lymphocyte, *Hi* histiocyte, *E* eosinophil, *P* plasma cell. Hematoxylin and eosin staining

Table 4.1 Composition of the microenvironment in different Hodgkin lymphoma (HL) subtypes

Subtype	EBV (%)	Background	T cells	Other cells
Nodular sclerosis	10–40	Nodular + fibrosis	CD4 > CD8, Th2, Treg > Th1	Eosinophils, histiocytes, fibroblasts, B cells, mast cells (neutrophils)
Mixed cellularity	75	Diffuse	CD4 > CD8, Th2, Treg > Th1	Eosinophils, histiocytes, plasma cells, B cells
Lymphocyte rich	40–80	Nodular or diffuse	CD4 > CD8	Histiocytes
Lymphocyte depleted (including HIV+)	80–100	Diffuse	–	Fibroblasts
Nodular lymphocyte predominant	~2	Nodular (+diffuse)	Th2, PD1+/CD57+ Tfh, CD4+/8+	Histiocytes, B cells

cellularity subtype (~75% EBV-positive) and is almost always absent in NLPHL [7]. Depending on the geographic locale, EBV is present in the HRS cells in 10–40% in nodular sclerosis cases. The percentage of EBV-positive lymphocyte-rich cHL cases is not very clear, but is probably between 40% and 80%. EBV infects more than 90% of the world population and establishes a lifelong latent infection in B cells in its host. Potent cytotoxic immune responses keep the number of EBV-infected B cells at approximately 1/100,000 and usually prevents EBV-driven malignant transformation in immunocompetent individuals. Accordingly, EBV-positive cHL cases contain slightly more CD8+ cytotoxic T cells in the reactive background compared to EBV-negative cHL cases [8].

4.1.3 Human Immunodeficiency Virus

In patients with an impaired immune response, cHL occurs more frequently. After solid organ transplantation, there is a small increase in the incidence of cHL that can largely be attributed to EBV-positive cHL. Human immunodeficiency virus (HIV)-infected individuals have an approximate 10 times increased risk of developing cHL [9]. In comparison to non-HIV-associated cHL, these tumors are more often EBV-associated, mixed cellularity and lymphocyte depletion subtypes, and usually contain more tumor cells. This may reflect a functional defect in the immune response, in particular to EBV, presumably caused by the impairment of CD4+ T cells by HIV. On the other hand, the importance of CD4+ T cells for supporting the growth of HRS cells is also illustrated in HIV-positive patients, in which an increase in the incidence of HIV-associated cHL has been observed after introduction of highly active antiretroviral therapy (HAART) [10].

4.1.4 T Cell Subsets in cHL

A unifying feature of the reactive infiltrate in virtually all cHL subtypes is the presence of large

numbers of CD4+ T cells. Besides being widely distributed in the background, these CD4+ T cells form a tight rosette around the tumor cells. T cells within these rosettes often have a distinct phenotype, which is different from the phenotype of the T cells that are located further away from the cHL tumor cells (Fig. 4.2).

In general, CD4+ T cells are divided into naive (CD45RA+) and memory (CD45RO+) subsets based on whether they have previously been stimulated by an antigen or not. A large subset of CD4+ T cells consists of the so-called helper T (Th) cells; these cells play an important role in helping other cells to induce an effective immune response. Th cells can be further divided into Th0 (naive), Th1 (cellular response), Th2 (humoral response), Th17 (IL-17 producing), and Treg (regulating responses of other cells) cells. The Treg cells can be further divided into Th3 (transforming growth factor- β (TGF- β) producing), Tr1 (IL-10 producing), and CD4+CD25+ Treg (originating from the thymus) subpopulations. Some, but not all, Treg cells express the transcription factor FoxP3.

The T cells in cHL consist mainly of CD4+ T cells that have a memory phenotype (CD45RO+) and express several activation markers including CD28, CD38, CD69, CD71, CD25, and HLA-DR, as well as markers like CD28, CTLA-4, and CD40L. However, these T cells lack expression of CD26 [11]. This lack of CD26 expression is most striking in the areas surrounding the tumor cells. CD26, dipeptidyl peptidase IV, regulates proteolytic processing of several chemokines, e.g., CCL5 (Rantes), CCL11 (Eotaxin), and CCL22 (MDC) [12]. CD26 is also associated with adenosine deaminase (ADA) and CD45RO and when interacting with anti-CD26 antibodies leads to enhanced T cell activation through triggering of the T cell receptor [13]. CD26 is preferentially expressed on CD4+CD45RO+ cells and is normally upregulated after activation. However, CD26 cannot be upregulated by ex vivo activation of the CD26-negative cells from cHL lesions. In general, a high CD26 expression level correlates with a Th1 subtype.

The transcription factor expression pattern indicates that the CD4+ T cells in cHL are predominantly Th2 (c-Maf) and Treg (FoxP3) [4, 14].




Fig. 4.2 Shaping the microenvironment in classical Hodgkin lymphoma (HL). Immunohistochemistry of classical HL cases. In the upper panel left, strong and specific staining of Hodgkin/Reed-Sternberg (HRS) cells for chemokine CCL17 (TARC). This chemokine

attracts CCR4+ lymphocytes (upper panel right). A large proportion of reactive T cells are Treg cells, as shown by positive staining for transcription factor FoxP3 (lower panel left) and activation marker CD25 (lower panel right)

The CD4+CD26⁻ T cell subset in cHL has reduced mRNA levels of Th1- and Th2-associated cytokines in comparison to the CD4+CD26⁺ T cells from cHL and CD4⁺ T cells (both CD26⁻ and CD26⁺) in reactive lymph nodes [15]. Based on much higher mRNA expression levels of IL-2RA (CD25), CCR4, FoxP3, CTLA4, TNFRSF4 (OX-40), and TNFRSF18 (GITR) observed in the CD4+CD26⁻ T cells from cHL, it has been postulated that these cells have a Treg phenotype (Fig. 4.2). In addition, mildly enhanced IL-17 levels can be observed both in CD4+CD26⁻ and CD4+CD26⁺ T cells from cHL in comparison to the T cells from tonsil. Upon stimulation, the CD4+CD26⁻ T cells fail to induce expression of cytokines, suggesting that the T cell population rosetting around the HRS cells or located in the direct vicinity of the HRS cells have an anergic phenotype (i.e., do not respond to stimulation)

[15]. Immunohistochemistry for several Treg-associated molecules demonstrates that the rosetting T cells in cHL express GITR, CCR4, and CD25, but not FoxP3. Scattered FoxP3-positive cells are present in the infiltrate, but only rarely in the direct vicinity of the HRS cells, whereas CTLA-4 shows a more diffuse presence [15]. Likewise, a small number of scattered IL-17-positive cells can be found in the reactive infiltrate. Th17 cells are generally pro-inflammatory, but given the abundance of TGF- β and IL-6 in the Hodgkin microenvironment, the observed IL-17-positive cells might be yet another type of regulatory cells, termed Treg17 cells. Although the vast majority of studies indicate that the CD4⁺ T cells in cHL are (anergic) Th2 cells and Treg cells, some studies showed a predominant Th1-type pattern in whole lymph node cell suspensions, with a mild increase in EBV-positive cHL [16]. These findings

are not contradictory, as these Th1-like cells are located mainly outside the areas where R-S cells and T cell rosettes are found [17, 18].

4.1.5 T Cell Subsets in NLPHL

The CD4+ T cells in NLPHL resemble the CD4+ T cells in cHL, regarding the expression of CD45RO, CD69, CTLA4, and CD28 and lack of CD26. However, the T cells in NLPHL do not express CD40L, and a significant proportion of the T cells that immediately surround the LP cells express CD57 and PD-1 [19, 20]. Similar to the Th2 cells in cHL, the rosetting cells in NLPHL strongly express the Th2-associated transcription factor c-Maf (Fig. 4.3; [4]).

Characterization of the cytokine profile of the CD4+CD57+ T cell subset shows lack of IL-2 and IL-4 mRNA, but elevated interferon- γ (IFN- γ) mRNA levels in comparison to CD57+ T cells from tonsils. Stimulation of these cells fails to induce IL-2 and IL-4 mRNA levels [21], which is similar to the lack of cytokine induction upon stimulation of the CD26- T cells in cHL. In normal tissue, CD4+CD57+ T cells are found almost exclusively in the light zone of reactive germinal centers and also lack CD40L expression. CD57 is known as an activation marker, but it has also been demonstrated to be a marker for senescent cells. Senescence is the phenomenon by which normal diploid cells lose the ability to divide, normally after about 50 cell divisions. PD-1+ T follicular helper cells are present in NLPHL;




Fig. 4.3 T cells in nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL). Immunohistochemistry of an NLPHL case showing a variable but usually high number of reactive T cells that express CD57. In this case these T cells form a rosette around the tumor cells (upper

panel left). The CD57+ T cells also express the transcription factor c-Maf, indicating a Th2-type nature (upper panel right). In addition, these cells express the T follicular helper cell-associated markers PD-1 (lower panel left) and BCL-6 (lower panel right)

these cells normally provide help to B cells during the germinal center reaction. Another cell population, consisting of CD4+CD8+ dual positive T cells, has been reported to be present in more than 50% of NLPHL tumors. A similar population was found in reactive lymph nodes with progressively transformed germinal centers, which can also be seen in conjunction with NLPHL. In normal peripheral blood, they constitute 1–2% of T cells. The function of these cells is ill defined, and currently they are considered to be potent immunosuppressors and/or to have high cytotoxic potential [22].

4.1.6 Fibrosis and Sclerosis

The presence of bands of collagen surrounding nodules and blood vessels is typical of the nodular sclerosis subtype. Several factors can induce the activation of fibroblasts and the subsequent deposition of extracellular matrix proteins. The Th2 cells in cHL might provide a profibrogenic microenvironment by the production of the Th2 cytokine IL-13. IL-13 is expressed at a higher level in nodular sclerosis than in mixed cellularity cHL. Moreover, the percentage of IL-13 receptor-positive fibroblasts is increased in nodular sclerosis cHL cases [23]. IL-13 stimulates collagen synthesis *in vitro* and also stimulates the production of TGF- β , another potent stimulator of fibrosis. TGF- β can interact with basic fibroblast growth factor (bFGF) to induce formation of fibrosis in cHL. In a mouse model for fibrosis, the simultaneous application of TGF- β and bFGF causes persistent fibrosis [24]. Both TGF- β and bFGF are produced by HRS cells as well as the reactive background [25, 26]. They are produced more prominently in nodular sclerosis than in mixed cellularity cHL [27]. The third factor that stimulates fibroblasts in cHL is the engagement of CD40. CD40, a member of the tumor necrosis factor receptor (TNFR) superfamily, can be upregulated on fibroblasts by IFN- γ . The ligand of CD40 (CD40L) is present on activated T cells, mast cells, and eosinophils present in the cHL microenvironment.

4.1.7 Eosinophils, Plasma Cells, Mast Cells, and B Cells

Presence of eosinophils in the reactive infiltrate can be promoted by both IL-5, produced by Th2 cells, and by IL-9. In cHL patients with eosinophilia in the peripheral blood, HRS cells produce IL-5 and IL-9 [28]. In addition, eosinophils are attracted to cHL tissues by the production of the chemokine CCL11, especially in nodular sclerosis cHL. CCL11 levels can be enhanced by the production of tumor necrosis factor- α (TNF- α) by the HRS cells, which in turn can induce CCL11 production in fibroblasts. This process is specific for cHL since other lymphomas with tissue eosinophilia show no expression of CCL11 [29]. HRS cells also produce CCL28 (MEC), and expression of CCL28 correlates with the presence of eosinophils and plasma cells in cHL. CCL28 attracts eosinophils by signaling through the chemokine receptor CCR3 and attracts plasma cells through CCR10 [30]. CCL5 is produced at high levels by the reactive infiltrate in cHL and can attract eosinophils as well as mast cells. CCL5 and IL-9 may both contribute to the attraction of mast cells in cHL [31]. The stimulation and recruitment of eosinophils in cHL can be illustrated in bone marrow biopsies that often show enhanced granulopoiesis with many eosinophils in the absence of HRS cells. IL-6 produced by HRS cells in some cases of cHL may explain the presence of variable numbers of plasma cells [32]. B cells that express CD20, CD21, IgM, and bcl-6 can be found in the microenvironment of cHL [33]. It is possible that these cells are remnants of the original lymph node B cell areas. Plasma cells, mast cells, and eosinophils are generally absent in NLPHL.

4.2 Cross-Talk between HRS Cells and Microenvironment (Fig. 4.4)

4.2.1 Factors Supporting Tumor Growth

It is likely that HL tumor cells originate from a precursor B cell that has become addicted to




Fig. 4.4 Schematic overview of the cross-talk between Hodgkin/Reed-Sternberg (HRS) cells and the microenvironment. HRS cells attract specific subsets of cells by producing chemokines, are dependent on growth factors, and

use mechanisms of immunosuppression and immune escape. Arrows indicate stimulating effects; the other lines indicate inhibitory effects

activating and growth-supporting stimuli during a deregulated immune response. Many additional events are needed to account for the highly deregulated malignant phenotype of HRS and LP cells. Although the tumor cells attain multiple alternative mechanisms to circumvent the dependence on growth-stimulating signals from the reactive infiltrate, they usually are not self-sufficient at the time of diagnosis. This is reflected by the inability to generate cell lines from primary HL cell suspensions.

IL-3 can function as a growth factor for B cells and is produced by activated Th2 cells, mast cells, and eosinophils. Its functions include protection against apoptosis and stimulation of proliferation. Most HRS cells express the IL-3 receptor, and exogenous IL-3 promotes growth of cHL cell lines. Costimulation of HL cell lines with IL-3 and IL-9 results in a further enhancement of cell growth [34]. There is no evidence

that HRS cells produce IL-3, so this signaling pathway depends on IL-3 produced by the reactive infiltrate. In contrast, IL-7 is most likely an autocrine as well as a paracrine growth factor for HRS cells, since HRS cells express both the IL-7 receptor and produce IL-7 [35]. cHL cell lines also produce IL-7, albeit at very low levels, and anti-IL-7 treatment has some effect on cell growth. Addition of IL-7 to HL cell line cultures increased proliferation and protected against apoptosis. Moreover, fibroblasts isolated from cHL tissues are able to produce IL-7 [36]. Other growth factors important for HRS cells are IL-9, IL-13, IL-15, and, possibly, IL-6. IL-9 is expressed by the tumor cells and not by the infiltrating cells, and the IL-9 receptor is expressed on cHL tumor cells and mast cells. IL-9 supports tumor growth in cell lines and functions as an autocrine factor in cHL tissue [31]. IL-13 produced by HRS cells as well as the

surrounding T cells drives proliferation and is mostly autocrine [37]. Both IL-15 and the IL-15R are expressed by HRS cells. IL-15 induces proliferation of HL cell lines and protects them against apoptosis [38]. IL-6 is mainly produced by HRS cells and occasionally by the infiltrating cells [32]. In general, IL-6 is found at higher levels in EBV-positive cases [39]. IL-6 might have an autocrine effect although neutralizing antibodies have no effect on the growth of cHL cell lines.

The signaling of cytokines upon binding to their receptors leads to activation of the JAK-STAT pathway. This pathway is constitutively activated in HL cell lines [40, 41], and several of the STAT family members are expressed in HRS cells of primary cHL cases [42, 43]. In addition to the presence of cytokines, amplifications of 9p24.1, including the JAK2 gene locus found in part of the cHL cases [44], can further enhance constitutive activation of this pathway. Functional studies in cHL cell lines have shown that STAT3 is involved in proliferation [45], while STAT1 and STAT6 play a role in protection against apoptosis [46]. Binding of IL-21 to the IL-21R expressed on HL cell lines causes phosphorylation of STAT5 and induces proliferation [47].

HRS cells express several members of the TNFR superfamily including CD30, which has been used as a marker for cHL since the early 1980s. The CD30 ligand (CD30L) is expressed on eosinophils [48] and mast cells [49] that are present in the cHL infiltrate. Circulating eosinophils in cHL patients also have increased expression levels of CD30L [48]. Binding of CD30L to CD30 causes enhanced secretion of IL-6, TNF α , lymphotoxin- α , increased expression of ICAM-1 and B7, and, possibly, increased clonogenic growth and protection against apoptosis in cHL cell lines [50]. Another TNFR expressed on HRS cells is CD40. CD40 is generally found on B cells, and B cells can be activated through CD40. In vitro rosetting of activated CD4+ T cells around HRS cells is mediated through the CD40L adhesion pathway [51]. Engagement of CD40 is important for the prevention of apoptosis. Similar to stimulation of CD30, stimulation of HRS cell lines with CD40L causes enhanced secretion of several cytokines and upregulation of costimulatory molecules [50].

Several receptor tyrosine kinases (RTKs) are expressed by HRS cells and can have a role in cell growth. Their ligands are expressed on cells present in the microenvironment or by the HRS cells themselves. Inhibition of PDGFRA, expressed by the HL tumor cells, by imatinib blocks proliferation. Its ligand, PDGFA, is also produced by the HRS cells indicating autocrine signaling [52]. DDR1 [53] and DDR2 [52] can protect HRS cells from cell death by binding to collagen, which is present in the immediate surrounding of HRS cells. Knockdown of DDR1 decreases survival of the L428 cHL cell line [53]. TRKA, the receptor for NGF, is expressed by granulocytes [52], and TRK inhibition decreases growth of cHL cell lines [54]. EPHB1 and its ligand ephrin-B1 are both expressed by HRS cells [52]. The HGF receptor c-Met is expressed on HRS cells and inhibition causes G2/M cell cycle arrest in HL cell lines. HGF is produced by the tumor cells in a small group of patients and by dendritic reticulum cells [55]. Insulin-like growth factor receptor (IGF-1R) is expressed in 55% of cHL patients, and inhibition of IGF-1R decreases cell growth and induces G2/M cell cycle arrest in HL cell lines [56]. Its ligand IGF-1 is expressed by cells in the microenvironment [57]. PDGFRA, DDR2, EPHB1, RON, TRKA, and TRKB are found especially in EBV-negative HL [58], while DDR1 is upregulated by LMP1 [53].

The Notch1 receptor is an upstream regulator of NF κ B [59]. It is highly expressed by HRS cells and stimulation via Jagged1 induces proliferation and survival of cHL cell lines [60].

4.2.2 Shaping the Environment

In addition to the production of several growth factors, HRS cells also produce large amounts of chemokines to attract specific beneficial or non-reacting cells. The lack of CD26 on the T cells surrounding the HRS cells may result in an incapability to cleave chemokines and thereby modulates the chemotactic effects exerted by the HRS cells. The attraction of specific populations of cells is an important immune escape mechanism exerted by the tumor cells.

The most abundant and cHL-specific chemokine is CCL17 (TARC); it binds to CCR4 on Th2 cells, Treg cells, basophils, and monocytes. CCL17 is highly expressed by HRS cells in ~95% of cHL patients but not in NLPHL and most non-Hodgkin lymphomas [61, 62]. CCL17 can be measured in serum and plasma and is a sensitive and specific marker reflecting cHL tumor burden [63–67]. High expression levels of CCL17 might explain the influx of lymphocytes with a Th2- and Treg-like phenotype, and CCL17-positive cases are indeed associated with a higher percentage of CCR4-positive cells (Fig. 4.2; [62, 68]). In turn, Th2-type cytokines (IL-4, IL-13) can induce the production of CCL17 by HRS cells. CCR4-positive T cells are found especially in the rosettes immediately surrounding the HRS cells [15, 69]. CCL22 is another chemokine that has a similar function as CCL17. High CCL22 protein expression levels were found in the cytoplasm of HRS cells in 90–100% of cHL patients and also in tumor cells in the majority of NLPHL and non-HL patients [70–73]. CCL22 production can also be stimulated by Th2 cytokines, IL-4 and IL-13, and may reinforce the attraction of Th2 and Treg cells, initiated by CCL17. Stimulation of the IL-21 receptor on HRS by IL-21 activates STAT3, which can induce CCL20 (MIP3 α) production. CCL20 in turn attracts memory T cells and Treg cells [74]. HRS cells express both IL-21 and the IL-21 receptor, indicating presence of an autocrine signaling loop. The expression of some chemokines is more pronounced in EBV-positive cHL (i.e., CXCL9 and CXCL10), and as a result the composition of the reactive background is somewhat different from that in EBV-negative cHL, with a slightly higher proportion of CD8+ T cells in EBV-positive cases and more T cells with a Tr-1 phenotype (expressing LAG3, ITGA2, and ITGB2) [75]. T cell recruitment is also enhanced by the upregulation of adhesion molecules on endothelial cells, induced by LT α [76] produced by HRS cells [77].

In addition to attracting specific cell subsets by chemotaxis, HRS cells also shape their environment by inducing differentiation of specific T cell subsets that are favorable for HRS cell survival and growth. The expression of IL-13 by the

HRS cells stimulates differentiation of naïve T cells to Th2 cells [37]. The production of IL-7 by HRS cells and fibroblasts can induce proliferation of Tregs [36]. Also, cHL cell lines with antigen-presenting functions like KMH2 and L428 have been shown to promote the differentiation of Treg like cells in vitro (expressing CD4, CD25, FoxP3, CTLA4, and GITR and producing large amounts of IL-10). Interestingly, these cell lines can also induce the formation of CD4+ cytotoxic T cells (expressing granzyme B and TIA-1) that can kill tumor cells directly, suggesting that CD4+ cytotoxic T cells have the potential to attack tumor cells in vivo [78].

4.3 Immune Escape Mechanisms (Fig. 4.4)

4.3.1 Antigen Presentation

The importance of antigen presentation in the pathogenesis of cHL has been suggested by the association of specific HLA subtypes with increased cHL incidence. cHL is more common in Caucasians as compared to Asians and about 4.5% of cHL cases occur in families [79, 80]. A three- to sevenfold increased risk has been observed in first-degree relatives and siblings. In monozygotic twins, the co-twin has an approximate 100-fold increased risk of developing cHL compared to dizygotic twins [81]. From the 1970s, a number of serological HLA types have been associated with the occurrence of cHL. More recently, a genetic screen of the entire HLA region showed a strong association between the *HLA-A* gene and EBV-positive cHL and the HLA class II region with EBV-negative cHL [82, 83]. Four independent genome-wide association studies have confirmed that the HLA region is the strongest genetic susceptibility locus in cHL [84–87]. In EBV-positive cHL, it can be hypothesized that this association is related to insufficient presentation of EBV antigenic peptides. These antigenic peptides most likely are derived from the latency type II genes that are expressed in cHL, i.e., LMP1, LMP2, and EBV-related nuclear antigen 1 (EBNA1). EBV partially escapes cytotoxic

immune responses by downregulating immunodominant latent genes (*EBNA2* and *EBNA3*). In addition, the glycine-alanine repeat in *EBNA1* largely prevents its presentation by HLA class I by blocking its degradation into antigenic peptides through the proteasome [88]. However, subdominant immune responses to LMP2 and to a lesser extent LMP1 are present in healthy EBV-infected individuals [89]. In fact, adoptive immunotherapy in relapsed EBV-positive cHL has been used in some small studies with success. In these studies, peripheral blood from cHL patients was used to generate EBV-specific cytotoxic T cells in vitro, and these were reinfused. Some durable complete responses were observed, with better responses if the cytotoxic T cells were specifically targeted to LMP2 [90–92] (Fig. 4.4). Interestingly, the genetic association of the *HLA-A* gene with EBV-positive cHL is attributed to the presence of the HLA-A*01 type and absence of the HLA-A*02 type [93]. HLA-A*01 is known to have a low affinity for LMP2- and LMP1-derived antigenic peptides, while HLA-A*02 can present these peptides very well. This suggests that EBV-positive cHL is more likely to occur after primary EBV infection if an individual's set of HLA class I molecules cannot properly present LMP2 and LMP1 to the immune system [94].

4.3.2 HLA Class I Expression

Defects in the antigen-presenting pathways are very common in solid malignancies, as well as in many B cell lymphomas, and are an obvious mechanism to escape from antitumor immune responses. In EBV-negative cHL, less than 20% of cases retain expression of cell surface HLA class I on the HRS cells at the time of diagnosis. Paradoxically, HLA class I expression by HRS cells is retained in ~75% of EBV-positive cHL patients [95–97]. One common mechanism of HLA class I loss is presence of somatic mutations in the β 2-microglobulin gene. This leads to loss of β 2-microglobulin protein, which is necessary for HLA class I assembly and transport to the cell surface. Other mechanisms also appear to be involved as immunohistochemistry has shown cytoplasmic β 2-microglobulin expression in part

of the cases that lost HLA class I heavy chain expression [98]. These different mechanisms may indicate that downregulation of HLA class I is based on clonal selection by continuous cytotoxic immune responses. This may be related to the presence of antigenic peptides that are related to malignant transformation or disease progression. However, downregulation of HLA class I generally induces activation of natural killer (NK) cells. These cells contain HLA class I-specific inhibitory receptors and are sparse in the reactive infiltrate of cHL. The inhibitory receptors can also be engaged by the nonclassical HLA class I-like molecule known as HLA-G. In about two thirds of the HLA class I-negative cHL cases, the HRS cells indeed express HLA-G [98]. Besides NK cell inhibition, HLA-G might also induce Treg cells and inhibit cytotoxic T cell responses. Another immune escape mechanism consists of the proteolytic cleavage of MHC (HLA) class I-related chain-A (MIC-A) by ERp5 and ADAM10, which are both expressed by HRS cells. MIC-A is a membranous ligand for the activating NKG2D receptor present on cytotoxic T cells. In addition, the NKG2D receptor expression by these cytotoxic T cells is reduced in the presence of TGF- β [99].

4.3.3 HLA Class II Expression

HLA class II cell surface expression on HRS cells is lost in approximately 40% of all cHL patients [95]. In addition, translocations involving *CIITA* have been found in 15% of cHL patients and may result in partial downregulation of HLA class II expression [101]. The absence of HLA class II is weakly related to extranodal disease, EBV-negative status, and absence of HLA class I cell surface expression. Lack of HLA class II expression has been associated with adverse failure-free survival and relative survival and is independent of other prognostic factors [95]. It can be hypothesized that antigen presentation in the context of HLA class II is involved in recruitment and activation of CD4+ T cells early in cHL pathogenesis. Under the influence of immunomodulating mechanisms, these T cells are important in providing trophic factors for HRS cells

and also have a role in inhibiting Th1 responses. In the initial stages of cHL pathogenesis, HRS cells are probably highly dependent on the reactive infiltrate and expression of HLA class II, but as the lymphoma develops, this dependency may weaken because of alternative trophic and immunosuppressive strategies. Thus, downregulation of HLA class II without loss of viability of HRS cells might occur when the HRS cells have grown less dependent on the reactive infiltrate. This is supported by the finding that downregulation of HLA class II is associated with extranodal disease [95].

4.3.4 Immune Checkpoints

Immune checkpoint molecules have gained much attention due to their use as treatment targets. Both CTLA-4 and PD-1 blockade have shown remarkable results in cHL patients in clinical trials.

CTLA-4 is expressed exclusively on T cells upon activation. It gives an inhibitory signal early after T cell activation, by binding to CD80/CD86 with a higher avidity than the costimulatory molecule CD28. This limits T cell activation and proliferation [101, 102]. Interestingly, CTLA-4 is present on the characteristic CD26⁺ T cells in HL [15]. Moreover, HL cell lines are able to induce differentiation of naïve T cells into CTLA4⁺ Tregs [78]. So far, two clinical trials have exploited the use of a monoclonal antibody targeting CTLA-4 in relapsed and refractory HL after allogeneic hematopoietic cell transplantation. Objective response rates were observed in 2 out of 14 and 1 out of 7 cases [103, 104].

The interaction partner of PD-L1, PD-1, is present on activated T cells, B cells, macrophages (which also express PD-L1), and NK cells within the microenvironment [105, 106]. PD-L1 is highly expressed on HRS cells [105, 107], due to a selective amplification of the PD-L1 region on 9p24.1 [44], activation of AP-1 and LMP-1 [107], or chromosomal alterations involving the CIITA locus [100]. Anti-PD-1 therapy in relapsed and refractory HL patients, using the monoclonal antibodies nivolumab or pembrolizumab, showed objective response rates in 65–87% of the cHL

patients [108–111]. The mechanism of action of PD-1 blockade in HL remains unknown, but multiple mechanisms have been studied. In contrast to solid tumors where CD8⁺ cytotoxic T cells seem to be the main effector cells [112], CD4⁺ T cells might have an important role in mediating the antitumor immune response in HL. CD8⁺ T cells recognize the tumor cells through (neo)antigens presented in the context of HLA class I, which can ultimately lead to eradication of the tumor cells. However, HLA class I is often absent on HRS cells, making a central role for CD8⁺ T cells in immune checkpoint efficacy unlikely [96]. In HL, the inflammatory infiltrate is mainly dominated by CD4⁺ T cells, which are more often in direct contact with the HRS cells when compared to CD8⁺ T cells. In addition, CD4⁺PD-1⁺ T cells are more frequently bound to PD-L1⁺ HRS cells [113]. The majority of complete responders to nivolumab lack membranous HLA class I expression, while being positive for membranous HLA class II expression. Also, presence of HLA class II is predictive for a prolonged progression-free survival in patients treated with nivolumab >12 months after myeloablative autologous stem cell transplantation, in contrast to presence of HLA class I [114]. Although many studies on PD-1 blockade focused on T cells, expression of PD-1 on T cells in direct contact with HRS cells is rare, and their numbers are significantly lower in cases with PD-L1 gain [115]. Interestingly, exhausted PD-1⁺ CD3⁺CD56^{hi}CD16⁺ NK cells are enriched in HL, and their activation can be inhibited by PD-L1⁺CD163⁺CD14⁺ tumor-associated macrophages, which are also increased in HL. This inhibition was effectively reversed by PD-1 blockade [106]. This indicates the importance of other cell types in responses to PD-1 blockade that are currently less well characterized.

An interesting molecule with regard to the role of CD4⁺ T cells in responses to anti-PD-1 therapy is LAG-3. LAG-3 is an immune checkpoint molecule expressed on activated T cells, NK cells, B cells, and plasmacytoid dendritic cells [116]. The main interaction partner for LAG-3 is HLA class II, to which LAG-3 binds with higher affinity than CD4 [117]. LAG-3 is upregulated on Tregs, and LAG-3-positive lymphocytes are enriched in the

proximity of HRS cells [118, 119]. Increased LAG-3 expression was observed especially in EBV-positive cHL cases [118, 120]. Interestingly, the percentage of LAG-3-positive cells was enriched in CD4+ T cells that express a high intracellular CTLA-4 and GITR, but not FOXP3+ [118]. The GITR^{hi} CD4+ T cells are frequently in direct contact with HRS cells [15]. Moreover, CD4+LAG-3+ cells are significantly expanded in patients with active disease, which is in concordance with the ability of HL cell line supernatant to increase expansion of CD4+LAG-3+ regulatory T cells within PBMCs. In addition, higher FOXP3 and LAG-3 expression on tumor-infiltrating lymphocytes is associated with decreased LMP1- and LMP2-specific CD8+ T cell function [118]. Altogether this implicates an important role for LAG-3 in inhibiting (EBV) mediated cellular immunity in HL and points to LAG-3 as an interesting treatment target in combination with PD-1 blockade.

Currently, more and more immune checkpoint molecules are emerging as potential targets for therapy. Some of these are less well studied in the context of HL. For example, HRS cells express HVEM and CD200/CD200R [121] in addition to the earlier mentioned checkpoints, whereas TIM-3+ T cells are present within the inflammatory infiltrate [120], indicating the complexity of immunosuppressive mechanisms within the HL microenvironment.

4.3.5 Immunosuppression

As normal B cells are professional antigen-presenting cells, HRS cells are expected to present antigens to the immune system, at least early in disease pathogenesis. Indeed, most components of the HLA class I and HLA class II antigen-presenting pathways have been detected in the HRS cells at the time of diagnosis. However, Th1 cells are not actively attracted by the HRS cells and CD8+ T cells are relatively scarce. Moreover, HRS cells have gained the capacity to prevent CD8+ T cells from attacking by producing high amounts of the strongly immu-

nosuppressive cytokines TGF- β and IL-10. TGF- β is produced by HRS cells in nodular sclerosis cHL [25, 26], whereas IL-10 is more frequently found in EBV-positive (mixed cellularity) cHL [122, 123]. In normal cells, TGF- β is produced in an inactive form, which can be activated by acidification. TGF- β produced by cHL cell lines is active at a physiological pH and has a high molecular weight [124]. The same high molecular weight form of TGF- β can also be found in the urine of cHL patients [125] indicating that in patients HRS cells are able to produce the active TGF- β form.

Tregs present in the microenvironment of cHL are highly immunosuppressive and contain Tr1 (IL-10-producing Tregs) as well as CD4+CD25+ Tregs. IL-10, cell-cell contact, and CTLA4 play a main role in executing their immunosuppressive function [126]. In addition, HRS cells express galectin-1, an animal lectin, which can cause apoptosis in activated T cells, induce differentiation into Treg cells, and contribute to the elimination of an effective antitumor response in cHL [127]. Galectin-1 expression blocks CD8+ T cell responses against LMP1 and LMP2 in EBV-positive cHL [128]. HRS cells express FAS and the FAS ligand. However, there are some mechanisms protecting the HRS cells from apoptosis induction, such as FAS mutations in a small proportion of cases and c-FLIP overexpression in all cases [129]. Presumably, activated Th1 and CD8+ T cells expressing FAS are driven into apoptosis by the FAS ligand expression on the HRS cells. Also, indoleamine 2,3-dioxygenase (IDO), a known immunosuppressor, is expressed by histiocytes, dendritic cells, and endothelial cells in the microenvironment of cHL. IDO is found more often in EBV-positive HL, upregulates the number of Tregs [130], and potentially blocks the CD8+ T cell response [131]. In EBV-positive cHL, the Th1-inducing cytokine IL-12 is expressed in T cells surrounding the HRS cells, and its presence suggests that these T cells have the potential to induce antitumor activity [132]. However, an EBV-induced IL-12-related cytokine called EB13 can block this Th1 response and is produced by HRS cells [133].

4.4 Prognostic Impact of the Microenvironment

Several research groups studied the cHL reactive infiltrate in relation to prognosis. Gene expression profiling of whole tissue and subsequent validation by immunohistochemistry showed that high numbers of CD68-positive cells are related to adverse outcome [134]. In a meta-analysis of almost 3000 patients, a high density of CD68+ tumor-associated macrophages predicted overall survival, shorter progression-free survival, and poor disease survival in adult cHL [135]. Similar findings were obtained for CD163+ macrophages in this study. Analysis of 100 pediatric cHL revealed that especially M2 macrophages, characterized by co-expression of CD163 and c-Maf, are associated with poor survival, while M1 macrophages are associated with better survival [136]. In some studies tumor-associated macrophages were associated with EBV-positive tumors [135, 137] and presence of other cell types in the microenvironment, such as cytotoxic T cells [136] and mast cells [138]. Patients with a higher degree of mast cell infiltration or with tissue eosinophilia have an adverse failure-free survival, probably because the CD30L expression by these cell types is advantageous to the HRS cells [48, 49, 138].

Large numbers of Th2 cells in the microenvironment, as determined by c-Maf expression, correlate with improved disease-free survival [14]. Also, increased numbers of infiltrating Treg cells seem to correlate with improved survival as this effect was observed in two out of three studies [14, 139, 140]. Accordingly, a high percentage of activated CD8+ granzyme B+ T cells is a strong indicator of unfavorable clinical outcome [141]. More recently, a high proportion of Treg cells and the associated anergic phenotype of the microenvironment has been associated with a shorter time to progression [137]. A high CD4/CD8 T cell ratio was associated with treatment failure [142]. A high ratio of FoxP3 to cytotoxicity markers granzyme B [140] or Tia-1 [139] gives the best predictive value for a good prognosis and has also been correlated to the presence of macrophages

[136, 138], which might—in part—explain these effects. In other malignancies the presence of Tregs and the absence of CD8+ T cells have been associated with adverse prognosis. One explanation of this opposite effect might be that HRS cells are expected to behave more aggressively as they develop a stronger independency from the reactive infiltrate. In this situation a hostile microenvironment is allowed, because the HRS cells have acquired alternative immune evasive strategies. This theory fits with the adverse prognostic impact of absence of HLA class II expression.

4.5 Conclusion

The microenvironment is a fundamental component of the tumor mass and an essential pathogenetic factor in cHL and NLPHL. It supplies the tumor cells with growth factors and inhibits antitumor immune responses. In fact, it could be stated that the infiltrate does not consist of ‘innocent bystanders’ but contains ‘guilty opportunists’ [31]. As the tumor cells and the reactive infiltrate grow up together, there is an extensive cross-talk between these two components. The tumor cells actively attract and shape their environment for their own benefit and make use of a number of mechanisms to fend off antitumor immune responses.

References

1. Poppema S, Delsol G, Pileri SA et al (2008) Nodular lymphocyte predominant Hodgkin lymphoma. In: Swerdlow SH, Campo E, Harris NL et al (eds) WHO classification of tumours of haematopoietic and lymphoid tissues. IARC, Lyon
2. Stein H, Delsol G, Pileri SA et al (2016) Classical Hodgkin lymphoma, introduction. In: Swerdlow SH, Campo E, Harris NL et al (eds) WHO classification of tumours of haematopoietic and lymphoid tissues. IARC, Lyon
3. Fan Z, Natkunam Y, Bair E, Tibshirani R, Warnke RA (2003) Characterization of variant patterns of nodular lymphocyte predominant Hodgkin lymphoma with immunohistologic and clinical correlation. *Am J Surg Pathol* 27:1346–1356
4. Atayar C, van den Berg A, Blokzijl T et al (2007) Hodgkin lymphoma associated T-cells exhibit a

- transcription factor profile consistent with distinct lymphoid compartments. *J Clin Pathol* 60:1092–1097
5. Carbone A, Ghoghini A, Cabras A et al (2009) Differentiating germinal center-derived lymphomas through their cellular microenvironment. *Am J Hematol* 84:435–438
 6. Sattarzadeh A, Visser L, Rutgers B, Diepstra A, van den Berg A (2016) Characterization of the microenvironment of nodular lymphocyte-predominant Hodgkin lymphoma. *Int J Mol Sci* 17:e2127
 7. Huppmann AR, Nicolae A, Slack GW et al (2014) EBV may be expressed in the LP cells of nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL) in both children and adults. *Am J Surg Pathol* 38:316–324
 8. Oudejans JJ, Jiwa NM, Kummer JA et al (1996) Analysis of major histocompatibility complex class I expression on Reed-Sternberg cells in relation to the cytotoxic T-cell response in Epstein-Barr virus-positive and -negative Hodgkin's disease. *Blood* 87:3844–3851
 9. Goedert JJ, Cote TR, Virgo P et al (1998) Spectrum of AIDS-associated malignant disorders. *Lancet* 351:1833–1839
 10. Biggar RJ, Jaffe ES, Goedert JJ et al (2006) Hodgkin lymphoma and immunodeficiency in persons with HIV/AIDS. *Blood* 108:3786–3791
 11. Poppema S (1996) Immunology of Hodgkin's disease. *Baillieres Clin Haematol* 9:447–457
 12. Wolf M, Albrecht S, Marki C (2008) Proteolytic processing of chemokines: implications in physiological and pathological conditions. *Int J Biochem Cell Biol* 40:1185–1198
 13. Von Bonin A, Huhn J, Fleischer B (1998) Dipeptidyl-peptidase IV/CD26 on T cells: analysis of an alternative T-cell activation pathway. *Immunol Rev* 161:43–53
 14. Schreck S, Friebel D, Buettner M et al (2009) Prognostic impact of tumour-infiltrating Th2 and regulatory cells in classical Hodgkin lymphoma. *Hematol Oncol* 27:31–39
 15. Ma Y, Visser L, Blokzijl T et al (2008) The CD4+CD26– T-cell population in classical Hodgkin's lymphoma displays a distinctive regulatory T-cell profile. *Lab Invest* 88:482–490
 16. Greaves P, Clear A, Owen A et al (2013) Defining characteristics of classical Hodgkin lymphoma microenvironment T helper cells. *Blood* 122:2856–2863
 17. Wu R, Sattarzadeh A, Rutgers B, Diepstra A, van den Berg A, Visser L (2016) The microenvironment of classical Hodgkin lymphoma: heterogeneity by Epstein-Barr virus presence and location within the tumor. *Blood Cancer J* 6:e417
 18. Cader FZ, Schackmann RCJ, Hu X et al (2018) Mass cytometry of Hodgkin lymphoma reveals a CD4(+) regulatory T-cell-rich and exhausted T-effector microenvironment. *Blood* 132:825–836
 19. Nam-Cha SH, Roncador G, Sanchez-Verde L et al (2008) PD-1, a follicular T-cell marker useful for recognizing nodular lymphocyte-predominant Hodgkin lymphoma. *Am J Surg Pathol* 32:1252–1257
 20. Sattarzadeh A, Diepstra A, Rutgers B, van den Berg A, Visser L (2015) CD57+ T-cells are a subpopulation of T-follicular helper cells in nodular lymphocyte-predominant Hodgkin lymphoma. *Exp Hematol Oncol* 4:27
 21. Atayar C, Poppema S, Visser L et al (2006) Cytokine gene expression profile distinguishes CD4+/CD57+ T-cells of nodular lymphocyte predominance type of Hodgkin lymphoma from their tonsillar counterparts. *J Pathol* 208:423–430
 22. Rahemtullah A, Harris NL, Dorn ME et al (2008) Beyond the lymphocyte predominant cell: CD4+CD8+ T-cells in nodular lymphocyte predominant Hodgkin lymphoma. *Leuk Lymphoma* 49:1870–1878
 23. Ohshima K, Akaiwa M, Umeshita R et al (2001) Interleukin-13 and interleukin-13 receptor in Hodgkin's disease: possible autocrine mechanism and involvement in fibrosis. *Histopathology* 38:368–375
 24. Shinozaki M, Kawara S, Hayashi N et al (1997) Induction of subcutaneous tissue fibrosis in newborn mice by transforming growth factor- β – simultaneous application with basic growth factor causes persistent fibrosis. *Biochem Biophys Res Commun* 237:292–296
 25. Kadin M, Butmarc J, Elovic A et al (1993) Eosinophils are the major source of transforming growth factor- β 1 in nodular sclerosing Hodgkin's disease. *Am J Pathol* 142:11–16
 26. Newcom SR, Gu L (1995) Transforming growth factor beta 1 messenger RNA in Reed-Sternberg cells in nodular sclerosing Hodgkin's disease. *J Clin Pathol* 48:160–163
 27. Ohshima K, Sugihara M, Suzumiya J et al (1999) Basic fibroblast growth factor and fibrosis in Hodgkin's disease. *Pathol Res Pract* 195:149–155
 28. Samoszuk M, Nansen L (1990) Detection of interleukin-5 messenger RNA in Reed-Sternberg cells of Hodgkin's disease with eosinophilia. *Blood* 75:13–16
 29. Jundt F, Anagnostopoulos I, Bommert K et al (1999) Hodgkin/Reed-Sternberg cells induce fibroblasts to secrete eotaxin, a potent chemoattractant for T cells and eosinophils. *Blood* 94:2065–2071
 30. Hanamoto H, Nakayama T, Miyazato H (2004) Expression of CCL28 by Reed-Sternberg cells defines a major subtype of classical Hodgkin's disease with frequent infiltration of eosinophils and/or plasma cells. *Am J Pathol* 164:997–1006
 31. Glimelius I, Edstrom A, Amini RM et al (2006) IL-9 expression contributes to the cellular composition in Hodgkin lymphoma. *Eur J Haematol* 76:278–283

32. Jucker M, Abts H, Li W et al (1991) Expression of interleukin-6 and interleukin-6 receptor in Hodgkin's disease. *Blood* 77:2413–2418
33. Tudor CS, Distel LV, Eckhardt J et al (2013) B cells in classical Hodgkin lymphoma are important actors rather than bystanders in the local immune reaction. *Hum Pathol* 44:2475–2486
34. Aldinucci D, Poletto D, Nanni P et al (2002) Expression of functional interleukin-3 receptors on Hodgkin and Reed-Sternberg cells. *Am J Pathol* 160:585–596
35. Foss HD, Hummel M, Gottstein S et al (1995) Frequent expression of IL-7 gene transcripts in tumor cells of classical Hodgkin's disease. *Am J Pathol* 146:33–39
36. Cattaruzza L, Gloghini A, Olivo K et al (2009) Functional coexpression of interleukin (IL)-7 and its receptor (IL-7R) on Hodgkin and Reed-Sternberg cells: involvement of IL-7 in tumor cell growth and microenvironmental interactions of Hodgkin's lymphoma. *Int J Cancer* 125:1092–1101
37. Kapp U, Yeh WC, Patterson B et al (1999) Interleukin 13 is secreted by and stimulates the growth of Hodgkin and Reed-Sternberg cells. *J Exp Med* 189:1939–1946
38. Ullrich K, Blumenthal-Barby F, Lamprecht B et al (2015) The IL-15 cytokine system provides growth and survival signals in Hodgkin lymphoma and enhances the inflammatory phenotype of HRS cells. *Leukemia* 29:1213–1218
39. Herbst H, Samol J, Foss HD et al (1997) Modulation of interleukin-6 expression in Hodgkin and Reed-Sternberg cells by Epstein-Barr virus. *J Pathol* 182:299–306
40. Cochet O, Frelin C, Peyron J-F, Imbert V (2006) Constitutive activation of STAT proteins in the HDLM-2 and L540 Hodgkin lymphoma-derived cell lines supports cell survival. *Cell Signal* 18:449–455
41. Kube D, Holtick U, Vockerodt M et al (2001) STAT3 is constitutively activated in Hodgkin cell lines. *Blood* 98:762–770
42. Hinz M, Lemke P, Anagnostopoulos I, Hacker C et al (2002) Nuclear factor kappaB-dependent gene expression profiling of Hodgkin's disease tumor cells, pathogenetic significance, and link to constitutive signal transducer and activator of transcription 5a activity. *J Exp Med* 196:605–617
43. Skinmider BF, Elia AJ, Gascoyne RD et al (2002) Signal transducer and activator of transcription 6 is frequently activated in Hodgkin and Reed-Sternberg cells of Hodgkin lymphoma. *Blood* 99:618–626
44. Green MR, Rodig S, Juszczynski P et al (2012) Constitutive AP-1 activity and EBV infection induce PD-L1 in Hodgkin lymphomas and posttransplant lymphoproliferative disorders; implications for targeted therapy. *Clin Cancer Res* 18:1611–1618
45. Baus D, Pfitzner E (2006) Specific function of STAT3, SOCS1, and SOCS3 in the regulation of proliferation and survival of classical Hodgkin lymphoma cells. *Int J Cancer* 118:1404–1413
46. Baus D, Nonnenmacher F, Jankowski S et al (2009) STAT6 and STAT1 are essential antagonistic regulators of cell survival in classical Hodgkin lymphoma cell line. *Leukemia* 23:1885–1893
47. Scheeren FA, Diehl SA, Smit LA et al (2008) IL-21 is expressed in Hodgkin lymphoma and activates STAT5: evidence that activated STAT5 is required for Hodgkin lymphomagenesis. *Blood* 111:4709–4715
48. Pinto A, Aldinucci D, Gloghini A et al (1996) Human eosinophils express functional CD30 ligand and stimulate proliferation of a Hodgkin's disease cell line. *Blood* 88:3299–3305
49. Molin D, Edstrom A, Glimelius I et al (2002) Mast cell infiltration correlates with poor prognosis in Hodgkin's lymphoma. *Br J Haematol* 119:122–124
50. Grüss HJ, Ulrich D, Braddy S et al (1995) Recombinant CD30 ligand and CD40 ligand share common biological activities on Hodgkin and Reed-Sternberg cells. *Eur J Immunol* 25:2083–2089
51. Carbone A, Gloghini A, Gattei V et al (1995) Expression of functional CD40 antigen on Reed-Sternberg cells and Hodgkin's disease cell lines. *Blood* 85:780–789
52. Renné C, Willenbrock K, Küppers R et al (2005) Autocrine- and paracrine-activated receptor tyrosine kinases in classic Hodgkin lymphoma. *Blood* 105:4051–4059
53. Cader FZ, Vockerodt M, Bose S et al (2013) The EBV oncogene LMP1 protects lymphoma cells from cell death through the collagen-mediated activation of DDR1. *Blood* 122:4237–4245
54. Renné C, Minner S, Küppers R et al (2008) Autocrine NGF β /TRKA signaling is an important survival factor for Hodgkin lymphoma derived cell lines. *Leukemia Res* 32:163–167
55. Xu C, Plattel W, van den Berg A et al (2012) Expression of the c-met oncogene by tumor cells predicts a favorable outcome in classical Hodgkin's lymphoma. *Haematologica* 97:572–578
56. Liang Z, Diepstra A, Xu C et al (2014) Insulin-like growth factor 1 receptor is a prognostic factor in classical Hodgkin lymphoma. *PLOSone* 9:e87474
57. Eppler E, Janas E, Link K et al (2015) Insulin-like growth factor I is expressed in classical and nodular lymphocyte-predominant Hodgkin's lymphoma tumour and microenvironmental cells. *Cell Tissue Res* 359:841–851
58. Renné C, Hinsch N, Willenbrock K et al (2007) The aberrant coexpression of several receptor tyrosine kinases is largely restricted to EBV-negative cases of classical Hodgkin's lymphoma. *Int J Cancer* 120:2504–2509
59. Schwarzer R, Dörken B, Jundt F (2012) Notch is an essential upstream regulator of NF- κ B and is relevant for the survival of Hodgkin and Reed-Sternberg cells. *Leukemia* 26:806–813
60. Jundt F, Anagnostopoulos I, Förster R et al (2002) Activated Notch1 signaling promotes tumor cell proliferation and survival in Hodgkin and anaplastic large cell lymphoma. *Blood* 99:3398–3403

61. Peh SC, Kim LH, Poppema S (2001) TARC, a CC chemokine, is frequently expressed in classic Hodgkin lymphoma but not in NLP Hodgkin lymphoma, T-cell-rich B-cell lymphoma, and most cases of anaplastic large cell lymphoma. *Am J Surg Pathol* 25:925–929
62. Van den Berg A, Visser L, Poppema S (1999) High expression of the CC chemokine TARC in Reed-Sternberg cells. A possible explanation for the characteristic T-cell infiltrate in Hodgkin's lymphoma. *Am J Pathol* 154:1685–1691
63. Niens M, Visser L, Nolte IM et al (2008) Serum chemokine levels in Hodgkin lymphoma patients: highly increased levels of CCL17 and CCL22. *Br J Haematol* 140:527–536
64. Wehrauch MR, Manzke O, Beyer M et al (2005) Elevated levels of CC thymus and activation-related chemokine (TARC) in primary Hodgkin's disease: potential for a prognostic factor. *Cancer Res* 65:5516–5519
65. Platel WJ, van den Berg A, Visser L et al (2012) Plasma thymus and activation-regulated chemokine as an early response marker in classical Hodgkin's lymphoma. *Haematologica* 97:410–415
66. Sauer M, Plütschow A, Jachimowicz RD et al (2013) Baseline serum TARC levels predict therapy outcome in patients with Hodgkin lymphoma. *Am J Hematol* 88:113–115
67. Platel WJ, Alsada ZN, van Imhoff GW, Diepstra A, van den Berg A, Visser L (2016) Biomarkers for evaluation of treatment response in classical Hodgkin lymphoma: comparison of sGalectin-1, sCD163 and sCD30 with TARC. *Br J Haematol* 175(5):868–875
68. Ohshima K, Tutiya T, Yamaguchi T et al (2002) Infiltration of Th1 and Th2 lymphocytes around Hodgkin and Reed-Sternberg (H&RS) cells in Hodgkin disease: relation with expression of CXC and CC chemokines on H&RS cells. *Int J Cancer* 98:567–572
69. Ishida T, Ishii T, Inagaki A et al (2006) Specific recruitment of CC chemokine receptor 4-positive regulatory T cells in Hodgkin lymphoma fosters immune privilege. *Cancer Res* 66:5716–5722
70. Andrew DP, Chang MS, McNinch J et al (1998) STPC-1 (MDC) CC chemokine acts specifically on chronically activated Th2 lymphocytes and is produced by monocytes on stimulation with Th2 cytokines IL-4 and IL-13. *J Immunol* 16:5027–5038
71. Hedvat CV, Jaffe ES, Qin J et al (2001) Macrophage-derived chemokine expression in classical Hodgkin's lymphoma: application of tissue microarrays. *Mod Pathol* 14:1270–1276
72. Imai T, Chantray D, Raport CJ et al (1998) Macrophage-derived chemokine is a functional ligand for the CC chemokine receptor 4. *J Biol Chem* 273:1764–1768
73. Maggio E, van den Berg A, Visser L et al (2002) Common and differential chemokine expression patterns in RS cells of NLP, EBV positive and negative classical Hodgkin lymphomas. *Int J Cancer* 99:665–672
74. Lamprecht B, Kreher S, Anagnostopoulos I et al (2008) Aberrant expression of the Th2 cytokine IL-21 in Hodgkin lymphoma cells regulates STAT3 signaling and attracts Treg cells via regulation of MIP-3alpha. *Blood* 112:3339–3347
75. Morales O, Mrizak D, François V et al (2014) Epstein-Barr virus infection induces an increase of T regulatory type 1 cells in Hodgkin lymphoma patients. *Br J Haematol* 166:875–890
76. Fhu CW, Graham AM, Yap CT et al (2014) Reed-Sternberg cell-derived lymphotoxin-alpha activates endothelial cells to enhance T-cell recruitment in classical Hodgkin lymphoma. *Blood* 124:2973–2982
77. Foss H-D, Herbst H, Oelmann E et al (1993) Lymphotoxin, tumour necrosis factor and interleukin-6 gene transcripts are present in Hodgkin and Reed-Sternberg cells of most Hodgkin's disease cases. *Br J Haematol* 84:627–635
78. Tanijiri T, Shimizu T, Uehira K et al (2007) Hodgkin's Reed-Sternberg cell line (KM-H2) promotes a bidirectional differentiation of CD4+CD25+Foxp3+ T cells and CD4+ cytotoxic T lymphocytes from CD4+ naive T cells. *J Leukoc Biol* 82:576–584
79. Ferraris AM, Racchi O, Rapezzi D et al (1997) Familial Hodgkin's disease: a disease of young adulthood? *Ann Hematol* 74:131–134
80. Glaser SL, Hsu JL (2002) Hodgkin's disease in Asians: incidence patterns and risk factors in population-based data. *Leuk Res* 26:261–269
81. Mack TM, Cozen W, Shibata DK et al (1995) Concordance for Hodgkin's disease in identical twins suggesting genetic susceptibility to the young-adult form of the disease. *N Engl J Med* 332:413–418
82. Diepstra A, Niens M, Vellenga E et al (2005) Association with HLA class I in Epstein-Barr-virus-positive and with HLA class III in Epstein-Barr-virus-negative Hodgkin's lymphoma. *Lancet* 365:2216–2224
83. Niens M, van den Berg A, Diepstra A et al (2006) The human leukocyte antigen class I region is associated with EBV-positive Hodgkin's lymphoma: HLA-A and HLA complex group 9 are putative candidate genes. *Cancer Epidemiol Biomark Prev* 15:2280–2284
84. Enciso-Mora V, Broderick PMY et al (2010) A genome-wide association study of Hodgkin's lymphoma identifies new susceptibility loci at 2p16.1 (REL), 8q24.21 and 10p14 (GATA3). *Nat Genet* 42:1126–1130
85. Urayama KY, Jarrett RF, Hjalgrim H et al (2012) Genome-wide association study of classical Hodgkin lymphoma and Epstein-Barr virus status-defined subgroups. *J Natl Cancer Inst* 104:240–253
86. Cozen W, Li D, Best T et al (2012) A genome-wide meta-analysis of nodular sclerosing Hodgkin lymphoma identifies risk loci at 6p21.32. *Blood* 119:469–475

87. Sud A, Thomsen H, Orlando G et al (2018) Genome-wide association study implicates immune dysfunction in the development of Hodgkin lymphoma. *Blood* 132:1212–1218
88. Levitskaya J, Coram M, Levitsky V et al (1995) Inhibition of antigen processing by the internal repeat region of the Epstein–Barr virus nuclear antigen-1. *Nature* 375:685–688
89. Meij P, Leen A, Rickinson AB et al (2002) Identification and prevalence of CD8(+) T-cell responses directed against Epstein–Barr virus-encoded latent membrane protein 1 and latent membrane protein 2. *Int J Cancer* 99:93–99
90. Bollard CM, Aguilar L, Straathof KC et al (2004) Cytotoxic T lymphocyte therapy for Epstein–Barr virus+ Hodgkin’s disease. *J Exp Med* 200:1623–1633
91. Lucas KG, Salzman D, Garcia A et al (2004) Adoptive immunotherapy with allogeneic Epstein–Barr virus (EBV)-specific cytotoxic T-lymphocytes for recurrent EBV-positive Hodgkin disease. *Cancer* 100:1892–1901
92. Bollard CM, Gottschalk S, Torrano V et al (2014) Sustained complete responses in patients with lymphoma receiving autologous cytotoxic T lymphocytes targeting Epstein–Barr virus latent membrane proteins. *J Clin Oncol* 32:798–808
93. Niens M, Jarrett RF, Hepkema B et al (2007) HLA-A*02 is associated with a reduced risk and HLA-A*01 with an increased risk of developing EBV+ Hodgkin lymphoma. *Blood* 110:3310–3315
94. Jones K, Wockner L, Brennan RM et al (2016) The impact of HLA class I and EBV latency-II antigen-specific CD8+ T cells on the pathogenesis of EBV+ Hodgkin lymphoma. *Clin Exp Immunol* 183:206–220
95. Diepstra A, van Imhoff GW, Karim-Kos HE et al (2007) HLA class II expression by Hodgkin Reed–Sternberg cells is an independent prognostic factor in classical Hodgkin’s lymphoma. *J Clin Oncol* 25:3101–3108
96. Nijland M, Veenstra RN, Visser L et al (2017) HLA dependent immune escape mechanisms in B-cell lymphomas: implications for immune checkpoint inhibitor therapy? *Oncoimmunology* e1295202:6
97. Reichel J, Chadburn A, Rubinstein PG et al (2015) Flow sorting and exome sequencing reveal the oncogenome of primary Hodgkin and Reed–Sternberg cells. *Blood* 125:1061–1072
98. Diepstra A, Poppema S, Boot M et al (2008) HLA-G protein expression as a potential immune escape mechanism in classical Hodgkin’s lymphoma. *Tissue Antigens* 71:219–226
99. Zocchi MR, Catellani S, Canevali P et al (2012) High ERp5/ADAM10 expression in lymph node microenvironment and impaired NKG2D ligands recognition in Hodgkin lymphomas. *Blood* 119:1479–1489
100. Steidl C, Shah SP, Woolcock BW et al (2011) MHC class II transactivator CIITA is a recurrent gene fusion partner in lymphoid cancers. *Nature* 471:377–383
101. Walunas TL, Lenschow DJ, Bakker CY et al (1994) CTLA-4 can function as a negative regulator of T cell activation. *Immunity* 1:405–413
102. Alegre M, Frauwirth KA (2001) Thompson CB. T cell regulation by CD28 and CTLA-4. *Nat Rev Immunol* 1:220–228
103. Bashey A, Medina B, Corringham S et al (2009) CTLA-4 blockade with ipilimumab to treat relapse of malignancy after allogeneic hematopoietic cell transplantation. *Blood* 113:1581–1588
104. Davids MS, Kim HT, Bachireddy P et al (2016) Ipilimumab for patients with relapse after allogeneic transplantation. *N Engl J Med* 375:143–153
105. Yamamoto R, Nishikori M, Kitawaki T et al (2008) PD-1-PD-1 ligand interaction contributes to immunosuppressive microenvironment of Hodgkin lymphoma. *Blood* 15(111):3220–3224
106. Vari F, Arpon D, Keane C et al (2018) Immune evasion via PD-1/PD-L1 on NK-cells and monocytes/macrophages is more prominent in Hodgkin lymphoma than DLBCL. *Blood* 131:1809–1819
107. Green MR, Monti S, Rodig SJ et al (2010) Integrative analysis reveals selective 9p24.1 amplification, increased PD-1 ligand expression, and further induction via JAK2 in nodular sclerosing Hodgkin lymphoma and primary mediastinal large B-cell. *Blood* 116:3268–3277
108. Ansell SM, Lesokhin AM, Borrello I et al (2015) PD-1 blockade with nivolumab in relapsed or refractory Hodgkin’s lymphoma. *N Engl J Med* 372:311–319
109. Armand P, Engert A, Younes A et al (2018) Nivolumab for relapsed/refractory classical Hodgkin lymphoma after failure of autologous hematopoietic cell transplantation: extended follow-up of the multicohort single-arm phase II CheckMate 205 trial. *J Clin Oncol* 36:1428–1439
110. Younes A, Santoro A, Shipp M et al (2016) Nivolumab for classical Hodgkin’s lymphoma after failure of both autologous stem-cell transplantation and brentuximab vedotin: a multicentre, multicohort, single-arm phase 2 trial. *Lancet Oncol* 17:1283–1294
111. Chen R, Zinzani PL, Fanale MA et al (2017) Phase II study of the efficacy and safety of pembrolizumab for relapsed/refractory classic Hodgkin lymphoma. *J Clin Oncol* 35:2125–2132
112. Tumeq PC, Harview CL, Yearley JH et al (2014) PD-1 blockade induces responses by inhibiting adaptive immune resistance. *Nature* 515:568–571
113. Carey CD, Gusenleitner D, Lipschitz M et al (2017) Topological analysis reveals a PD-L1-associated microenvironmental niche for Reed–Sternberg cells in Hodgkin lymphoma. *Blood* 130:2420–2430
114. Roemer MGM, Redd RA, Cader FZ et al (2018) Major histocompatibility complex class II and programmed death ligand 1 expression predict outcome after programmed death blockade

- in classical Hodgkin lymphoma. *J Clin Oncol* 36:942–950
115. Muenst S, Hoeller S, Dirnhofer S et al (2009) Increased programmed death-1+ tumor-infiltrating lymphocytes in classical Hodgkin lymphoma substantiate reduced overall survival. *Hum Pathol* 40:1715–1722
 116. Goldberg MV, Drake CG (2011) LAG-3 in cancer immunotherapy. *Curr Top Microbiol Immunol* 344:269–278
 117. Huard B, Prigent P, Tournier M et al (1995) CD4/major histocompatibility complex class II interaction analyzed with CD4- and lymphocyte activation gene-3 (LAG-3)-Ig fusion proteins. *Eur J Immunol* 25:2718–2721
 118. Gandhi MK, Lambley E, Duraiswamy J et al (2006) Expression of LAG-3 by tumor-infiltrating lymphocytes is coincident with the suppression of latent membrane antigen-specific CD8+ T-cell function in Hodgkin lymphoma patients. *Blood* 108:2280–2289
 119. Camisaschi C, Casati C, Rini F et al (2010) LAG-3 expression defines a subset of CD4(+)/CD25(high) Foxp3(+) regulatory T cells that are expanded at tumor sites. *J Immunol* 184:6545–6551
 120. Duffield AS, Ascierto ML, Anders RA et al (2017) Th17 immune microenvironment in Epstein-Barr virus-negative Hodgkin lymphoma: implications for immunotherapy. *Blood Adv* 1:1324–1334
 121. Wein F, Weniger MA, Höing B et al (2017) Complex immune evasion strategies in classical Hodgkin lymphoma. *Cancer Immunol Res* 5:1122–1132
 122. Dukers DF, Jaspars LH, Vos W et al (2000) Quantitative immunohistochemical analysis of cytokine profiles in Epstein-Barr virus-positive and -negative cases of Hodgkin's disease. *J Pathol* 190:143–149
 123. Herbst H, Foss HD, Samol J et al (1996) Frequent expression of interleukin-10 by Epstein-Barr virus-harboring tumor cells of Hodgkin's disease. *Blood* 87:2918–2929
 124. Newcom SR, Kadin ME, Ansari AA et al (1988) L-428 nodular sclerosing Hodgkin's cell secretes a unique transforming growth factor-beta active at physiologic pH. *J Clin Invest* 82:1915–1921
 125. Newcom SR, Tagra KK (1992) High molecular weight transforming growth factor b is excreted in the urine in active nodular sclerosing Hodgkin's disease. *Cancer Res* 52:6768–6773
 126. Marshall NA, Christie LE, Munro LR et al (2004) Immunosuppressive regulatory T cells are abundant in the reactive lymphocytes of Hodgkin lymphoma. *Blood* 103:1755–1762
 127. Juszczynski P, Ouyang J, Monti S et al (2007) The API-1-dependent secretion of galectin-1 by Reed-Sternberg cells fosters immune privilege in classical Hodgkin lymphoma. *Proc Natl Acad Sci U S A* 104:13134–13139
 128. Gandhi MK, Moll G, Smith C et al (2015) Brief report Galectin-1 mediated suppression of Epstein-Barr virus-specific T-cell immunity in classic Hodgkin lymphoma. *Blood* 110:1326–1330
 129. Maggio EM, van den Berg A, de Jong D et al (2003) Low frequency of FAS mutations in Reed-Sternberg cells of Hodgkin's lymphoma. *Am J Pathol* 162:29–35
 130. Choe J-Y, Yun JY, Jeon YK et al (2014) Indoleamine 2,3-dioxygenase (IDO) is frequently expressed in stromal cells of Hodgkin lymphoma and is associated with adverse clinical features: a retrospective cohort study. *BMC Cancer* 14:335
 131. Soliman H, Mediavilla-Varela M, Antonia S (2010) Indoleamine 2,3-dioxygenase. Is it an immune suppressor? *Cancer J* 16:354–359
 132. Schwaller J, Tobler A, Niklaus G et al (1995) Interleukin-12 expression in human lymphomas and nonneoplastic lymphoid disorders. *Blood* 85:2182–2188
 133. Niedobitek G, Pazolt D, Teichmann M et al (2002) Frequent expression of the Epstein-Barr virus (EBV)-induced gene, EB13, an IL-12 p40-related cytokine, in Hodgkin and Reed-Sternberg cells. *J Pathol* 198:310–316
 134. Steidl C, Lee T, Shah SP et al (2010) Tumor-associated macrophages and survival in classical Hodgkin's lymphoma. *N Engl J Med* 362:875–885
 135. Guo B, Cen H, Tan X, Ke Q (2016) Meta-analysis of the prognostic and clinical value of tumor-associated macrophages in adult classical Hodgkin lymphoma. *BMC Med* 14:159
 136. Barros MHM, Segges P, Vera-Lozada G, Hassan R, Niedobitek G (2015) Macrophage polarization reflects T cell composition of tumor microenvironment in pediatric classical Hodgkin lymphoma and has impact on survival. *PLoS One* 10:1–19
 137. Hollander P, Rostgaard K, Smedby KE et al (2017) An anergic immune signature in the tumor microenvironment of classical Hodgkin lymphoma is associated with inferior outcome. *Eur J Haematol* 100:88–97
 138. Andersen MD, Kamper P, Nielsen PS et al (2016) Tumor-associated mast cells in classical Hodgkin's lymphoma: correlation with histological subtype, other tumour-infiltrating inflammatory cell subsets and outcome. *Eur J Haematol* 96:252–259
 139. Alvaro T, Lejeune M, Salvado MT et al (2005) Outcome in Hodgkin's lymphoma can be predicted from the presence of accompanying cytotoxic and regulatory T cells. *Clin Cancer Res* 11:1467–1473
 140. Kelley TW, Pohlman B, Elson P et al (2007) The ratio of Foxp3+ regulatory T cells to Granzyme B+ cytotoxic T/NK cells predicts prognosis in classical Hodgkin lymphoma and is independent of bcl-2 and MAL expression. *Am J Clin Pathol* 128:958–965
 141. Oudejans JJ, Jiwa NM, Kummer JA et al (1997) Activated cytotoxic T cells as prognostic marker in Hodgkin's disease. *Blood* 89:1376–1382
 142. Alonso-Álvarez S, Vidriales MB, Caballero MD et al (2017) The number of tumor infiltrating T-cell subsets in lymph nodes from patients with Hodgkin lymphoma is associated with the outcome after first line ABVD therapy. *Leuk Lymphoma* 58:1144–1152